| ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications C Maaser, A Sturm, SR Vavricka, T Kucharzik, G Fiorino, V Annese, ... Journal of Crohn's and Colitis 13 (2), 144-164K, 2019 | 1180 | 2019 |
| Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management M Harbord, R Eliakim, D Bettenworth, K Karmiris, K Katsanos, U Kopylov, ... Journal of Crohn's and Colitis 11 (7), 769-784, 2017 | 1172 | 2017 |
| ECCO guidelines on therapeutics in Crohn's disease: medical treatment J Torres, S Bonovas, G Doherty, T Kucharzik, JP Gisbert, T Raine, ... Journal of Crohn's and Colitis 14 (1), 4-22, 2020 | 1043 | 2020 |
| Optimizing anti-TNF treatments in inflammatory bowel disease S Ben-Horin, U Kopylov, Y Chowers Autoimmunity reviews 13 (1), 24-30, 2014 | 453 | 2014 |
| ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment M Adamina, S Bonovas, T Raine, A Spinelli, J Warusavitarne, A Armuzzi, ... Journal of Crohn's and Colitis 14 (2), 155-168, 2020 | 443 | 2020 |
| ECCO guidelines on therapeutics in ulcerative colitis: medical treatment T Raine, S Bonovas, J Burisch, T Kucharzik, M Adamina, V Annese, ... Journal of Crohn's and Colitis 16 (1), 2-17, 2022 | 415 | 2022 |
| Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases B Ungar, I Levy, Y Yavne, M Yavzori, O Picard, E Fudim, R Loebstein, ... Clinical Gastroenterology and Hepatology 14 (4), 550-557. e2, 2016 | 402 | 2016 |
| Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial A Lang, N Salomon, JCY Wu, U Kopylov, A Lahat, O Har-Noy, JYL Ching, ... Clinical gastroenterology and hepatology 13 (8), 1444-1449. e1, 2015 | 364 | 2015 |
| Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease S Ben–Horin, M Waterman, U Kopylov, M Yavzori, O Picard, E Fudim, ... Clinical Gastroenterology and Hepatology 11 (4), 444-447, 2013 | 354 | 2013 |
| Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab H Yanai, L Lichtenstein, A Assa, Y Mazor, B Weiss, A Levine, Y Ron, ... Clinical Gastroenterology and Hepatology 13 (3), 522-530. e2, 2015 | 349 | 2015 |
| The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab B Ungar, Y Chowers, M Yavzori, O Picard, E Fudim, O Har-Noy, ... Gut 63 (8), 1258-1264, 2014 | 346 | 2014 |
| ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects A Sturm, C Maaser, E Calabrese, V Annese, G Fiorino, T Kucharzik, ... Journal of Crohn's and Colitis 13 (3), 273-284, 2019 | 300 | 2019 |
| ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease T Kucharzik, P Ellul, T Greuter, JF Rahier, B Verstockt, C Abreu, ... Journal of Crohn's and Colitis 15 (6), 879-913, 2021 | 244 | 2021 |
| The immunogenic part of infliximab is the F (ab′) 2, but measuring antibodies to the intact infliximab molecule is more clinically useful S Ben-Horin, M Yavzori, L Katz, U Kopylov, O Picard, E Fudim, D Coscas, ... Gut 60 (1), 41-48, 2011 | 230 | 2011 |
| Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease R Battat, U Kopylov, T Bessissow, A Bitton, A Cohen, A Jain, M Martel, ... Clinical Gastroenterology and Hepatology 15 (9), 1427-1434. e2, 2017 | 229 | 2017 |
| European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] ECCO-ESGAR Guideline for Diagnostic Assessment in … C Maaser, A Sturm, SR Vavricka, T Kucharzik, G Fiorino, V Annese, ... J Crohns Colitis 13 (2), 144-164, 2019 | 228 | 2019 |
| Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis U Kopylov, S Ben-Horin, O Zmora, R Eliakim, LH Katz Inflammatory bowel diseases 18 (12), 2404-2413, 2012 | 209 | 2012 |
| Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease Y Mazor, R Almog, U Kopylov, D Ben Hur, A Blatt, A Dahan, M Waterman, ... Alimentary pharmacology & therapeutics 40 (6), 620-628, 2014 | 207 | 2014 |
| Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease U Kopylov, G Rosenfeld, B Bressler, E Seidman Inflammatory bowel diseases 20 (4), 742-756, 2014 | 201 | 2014 |
| European Crohn’s and Colitis Organisation [ECCO] M Harbord, R Eliakim, D Bettenworth, K Karmiris, K Katsanos, U Kopylov, ... Third European evidence-based consensus on diagnosis and management of …, 2016 | 195 | 2016 |
Eyal KlangMount Sinai Hospital, Icahn School of MedicineVerified email at mountsinai.org
